KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Medpace Holdings (MEDP) EBITDA: 2015-2024

Historic EBITDA for Medpace Holdings (MEDP) over the last 10 years, with Dec 2024 value amounting to $474.7 million.

  • Medpace Holdings' EBITDA rose 24.44% to $148.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $534.5 million, marking a year-over-year increase of 22.61%. This contributed to the annual value of $474.7 million for FY2024, which is 31.51% up from last year.
  • As of FY2024, Medpace Holdings' EBITDA stood at $474.7 million, which was up 31.51% from $361.0 million recorded in FY2023.
  • In the past 5 years, Medpace Holdings' EBITDA ranged from a high of $474.7 million in FY2024 and a low of $178.7 million during FY2020.
  • Its 3-year average for EBITDA is $377.8 million, with a median of $361.0 million in 2023.
  • Data for Medpace Holdings' EBITDA shows a peak YoY surged of 38.71% (in 2022) over the last 5 years.
  • Medpace Holdings' EBITDA (Yearly) stood at $178.7 million in 2020, then grew by 20.07% to $214.6 million in 2021, then spiked by 38.71% to $297.7 million in 2022, then climbed by 21.25% to $361.0 million in 2023, then surged by 31.51% to $474.7 million in 2024.